JPMorgan analyst Jessica Fye yesterday afternoon lowered her price target for Ionis Pharmaceuticals (IONS) to $25 citing "increased caution" following the announcement that severe platelet declines have been seen with the company's volanesorsen, in addition to GlaxoSmithKline (GSK) not moving forward with the CARDIO-TTR study for TTRRx. The analyst explained in a research note, "While nusinersen thus far appears to be spared from the effect, the platelet declines observed with volanesorsen clearly expand the scope of the side effect and raise questions on the overall platform." She keeps a Neutral rating on Ionis.